Pentosan polysulfate (PPS)

Pentosan polysulfate is technically not a peptide — it is a semi-synthetic sulfated polysaccharide, heparin-like in structure. It sits in this section because the peptide community treats it as one of theirs, and because it is the benchmark the rest of the section fails to meet.

Mechanism

Proposed disease-modifying actions in osteoarthritis include protection of cartilage proteoglycan and hyaluronan pools, shown in a rabbit steroid-injury model as far back as 1989, and stimulation of proliferation and chondrogenic differentiation of human bone-marrow mesenchymal precursor cells, with type II collagen deposition in vitro.

The human evidence

A randomized, double-blind, placebo-controlled pilot in 114 people with knee OA found that intramuscular PPS (3 mg/kg weekly for four weeks) improved stiffness, rest pain, and patient global assessment versus a Ringer's injection, with some gains persisting 8–12 weeks after the last dose. Two decades later it remains the only completed symptom-endpoint RCT — never independently replicated, and its lead author held PPS commercial interests.

The modern program belongs to Paradigm Biopharma. Its phase 2 biomarker RCT (n=61) reported a roughly 57% placebo-adjusted fall in synovial-fluid ARGS-aggrecan — a cartilage-degradation marker — after subcutaneous PPS, with favorable shifts in other cartilage biomarkers out to a year. That is biological signal, not proof of symptom benefit, and sponsor employees are among the authors. A single-arm oral pilot reported pain reduction, but with no control arm it is uninterpretable given OA's large placebo response.

What to watch

Two registered trials matter. PARA_OA_002 (phase 2/3 adaptive, ~602 participants) has produced positive company press releases but no peer-reviewed symptom results. The decisive readout is the pivotal phase 3, NCT06917404, which completed enrolment in 2026 with top-line results expected in the first quarter of 2027. Biomarkers like ARGS-aggrecan are surrogate outcomes; the phase 3's WOMAC-pain data are the ones that count.

The veterinary base

Unusually solid for this section: a randomized, blinded, placebo-controlled trial in 40 dogs after cruciate surgery showed faster gait recovery and lower degradation biomarkers, and a sponsor-run 20-dog trial in naturally occurring OA reported sustained pain and gait improvement plus increased cartilage volume at 26 weeks. PPS (Cartrophen Vet) is entrenched in equine practice — though the supporting Australian data are practitioner-perception surveys, not outcomes. Animal efficacy does not establish human efficacy, but here it coexists with actual human RCT signal.

Regulatory status and safety

The regulatory split matters. Oral PPS is FDA-approved as Elmiron for interstitial cystitis — not for osteoarthritis. Injectable PPS for OA is investigational in humans and approved only in veterinary medicine in some markets. Gray-market "PPS peptide" vials are neither.

The signature safety issue is ocular: chronic oral PPS (Elmiron) is associated with a distinctive pigmentary maculopathy, first described in a 2018 case series and now carried in US labeling. Risk appears tied to cumulative long-term exposure; its relevance to short injectable OA courses is unknown but not zero, and whether ophthalmic monitoring is warranted for repeated courses is an open question. PPS is heparin-like, so bleeding-risk caution and interaction potential with anticoagulants apply. Tolerability in the injectable trials so far has been acceptable. PPS is not on the WADA Prohibited List.

The caveat that spans everything

Nearly all modern PPS-for-OA data are Paradigm-sponsored, with employees and shareholders among the authors, and the strongest independent evidence is a 2005 pilot that was never confirmed. "Promising" is earned here — but the phase 3 readout is the event that will settle whether it was deserved.